Beamr video compression achieves up to 50% improvement for AVs
In a recent SEC filing, Syndax Pharmaceuticals Inc. (NASDAQ:SNDX), a $1.27 billion market cap biopharmaceutical company, disclosed that its Chief Financial Officer, Keith A. Goldan, sold 3,777 shares of the company’s common stock on February 10, 2025. According to InvestingPro data, the company maintains a FAIR financial health score despite not being profitable in the last twelve months. The shares were sold at an average price of $15.504 per share, amounting to a total transaction value of $58,558. Following this transaction, Goldan retains ownership of 90,746 shares in the company. According to the filing, the sale was made to cover tax withholding obligations related to the vesting of restricted stock units. With the company’s next earnings report due on March 5, 2025, investors can access comprehensive analysis and additional insights through InvestingPro’s detailed research reports, which highlight 8 more key factors affecting SNDX’s outlook.
In other recent news, Syndax Pharmaceuticals has been the focus of various analyst assessments and internal shifts. Jefferies maintained a Buy rating on Syndax, predicting key developments in 2025, including the launch of Revuforj with estimated sales reaching $67 million, and the expected inclusion of NPM1 in the NCCN guidelines. However, Scotiabank (TSX:BNS) reduced its price target for Syndax due to concerns about the FDA approval of revumenib, Syndax’s drug for acute myeloid leukemia.
Syndax also eliminated the role of Chief Medical (TASE:PMCN) Officer, leading to the departure of Dr. Catherine Madigan. The reason behind this organizational change was not elaborated upon.
In contrast, TD Cowen reiterated a Buy rating following the approval of Revuforj for the treatment of acute leukemias, projecting the drug to be commercially available soon. Similarly, H.C. Wainwright maintained a Buy rating and increased its price target after the FDA approved Revuforj for treating acute leukemia in certain patients. These are recent developments that investors should note.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.